RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Live Updates Make sure to refresh this page periodically for updates. Notable Upgrades and Downgrades Today 12:10 pm Here are ...

Investors set aside Trump's new tariff threats (0:35), Fed signals moderate pace in cutting rates (1:30). No exemption for ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

The last remaining asylum seekers being housed on the controversial floating accommodation barge Bibby Stockholm in southern England have left, local authorities said on Wednesday.

Lebanon's prime minister on Wednesday said the army will reinforce its presence in the south, urging Israel to withdraw and respect the terms of the ceasefire reached with Hezbollah.

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...

Amgen Inc.’s stock closed down 4.8% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...